Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v19-EN | Version v6-EN | |
|---|---|---|
| Language | English | English |
| Date Updated | 2023-04-13 | 2022-09-01 |
| Drug Identification Number | 02139545 | 02139545 |
| Brand name | POTASSIUM PHOSPHATES INJECTION, USP | POTASSIUM PHOSPHATES INJECTION, USP |
| Common or Proper name | Potassium Phosphates Injection, USP | Potassium Phosphates Injection, USP |
| Company Name | FRESENIUS KABI CANADA LTD | FRESENIUS KABI CANADA LTD |
| Ingredients | POTASSIUM PHOSPHATE DIBASIC POTASSIUM PHOSPHATE MONOBASIC | POTASSIUM PHOSPHATE DIBASIC POTASSIUM PHOSPHATE MONOBASIC |
| Strength(s) | 236MG 224MG | 236MG 224MG |
| Dosage form(s) | SOLUTION | SOLUTION |
| Route of administration | INTRAVENOUS INTRAVENOUS | INTRAVENOUS INTRAVENOUS |
| Packaging size | 50 ML | 50 ML |
| ATC code | B05XA | B05XA |
| ATC description | I.V. SOLUTION ADDITIVES | I.V. SOLUTION ADDITIVES |
| Reason for shortage | Disruption of the manufacture of the drug. | Disruption of the manufacture of the drug. |
| Anticipated start date | ||
| Actual start date | 2023-03-01 | 2022-08-01 |
| Estimated end date | 2023-05-01 | Unknown |
| Actual end date | 2023-04-12 | |
| Shortage status | Resolved | Actual shortage |
| Tier 3 Status | No | No |
| Company comments | Product is on backorder. Effective March 1, 2023, allocations of Potassium Phosphates Injection, USP 3 mmol/mL Phosphorus SD Vial 15 mL to cover 100% of historical monthly demand of 15 mL and 100% of historical monthly demand of 50 mL at a 3:1 ratio. Please see communication for further details. | Effective September 1, 2022 allocations for our 50 mL will be increased to cover 100% of 50mL demand plus 150% of 15 mL demand at a 2:1 ratio. Please see communication for further detaills. |
| Health Canada comments |